Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.
News|Articles|December 12, 2025
Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal
Author(s)Kevin Kunzmann
2025 data show the US is still failing to adequately identify and initiate care for deadly lung disease. Experts discuss what it will take to turn the tide on this public health issue.
Advertisement
Advertisement
Chronic lower respiratory diseases like COPD were the fourth leading clinical cause of death among Americans as of 2023, and lung cancer remains the deadliest cancer today.1 These are hardly new trends;
Related to this article
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Advertisement
Advertisement